Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302

por de Bono, Johann S., Smith, Matthew R., Saad, Fred, Rathkopf, Dana E., Mulders, Peter F.A., Small, Eric J., Shore, Neal D., Fizazi, Karim, De Porre, Peter, Kheoh, Thian, Li, Jinhui, Todd, Mary B., Ryan, Charles J., Flaig, Thomas W.
Publicado 2016

Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer

por Lorente, David, Olmos, David, Mateo, Joaquin, Bianchini, Diletta, Seed, George, Fleisher, Martin, Danila, Daniel C., Flohr, Penny, Crespo, Mateus, Figueiredo, Ines, Miranda, Susana, Baeten, Kurt, Molina, Arturo, Kheoh, Thian, McCormack, Robert, Terstappen, Leon W.M.M., Scher, Howard I., de Bono, Johann S.
Publicado 2016

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis

por Rydzewska, Larysa H.M., Burdett, Sarah, Vale, Claire L., Clarke, Noel W., Fizazi, Karim, Kheoh, Thian, Mason, Malcolm D., Miladinovic, Branko, James, Nicholas D., Parmar, Mahesh K.B., Spears, Melissa R., Sweeney, Christopher J., Sydes, Matthew R., Tran, NamPhuong, Tierney, Jayne F.
Publicado 2017